ASMB · Company research
Assembly Biosciences, Inc (ASMB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) stock price, news, quote and history - Yahoo Finance Australia | Assembly Biosciences, Inc. (ASMB) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 5, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences (Nasdaq:ASMB) - Stock Analysis - Simply Wall Street | Assembly Biosciences (Nasdaq:ASMB) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Sep 21, 2026 | neutral | 0 | 0.6 |
| $ASMB stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $ASMB stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 15, 2026 | neutral | 0 | 0.6 |
| Understanding Momentum Shifts in (ASMB) - Stock Traders Daily | Understanding Momentum Shifts in (ASMB) Stock Traders Daily | View source ↗ | Stock Traders Daily | Sep 14, 2026 | neutral | 0 | 0.6 |
| Assembly Bio schedules a live webcast for Sept. 16 - Stock Titan | Assembly Bio schedules a live webcast for Sept. 16 Stock Titan | View source ↗ | Stock Titan | Sep 10, 2026 | neutral | 0 | 0.6 |
| A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan | A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences (ASMB) Shares U.S. Development Costs and Pr - GuruFocus | Assembly Biosciences (ASMB) Shares U.S. Development Costs and Pr GuruFocus | View source ↗ | GuruFocus | Sep 8, 2026 | neutral | 0 | 0.6 |
| Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet - Zacks Investment Research | Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 20, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha | Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal Seeking Alpha | View source ↗ | Seeking Alpha | Aug 16, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds - Simply Wall Street | Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds Simply Wall Street | View source ↗ | Simply Wall Street | Aug 14, 2026 | neutral | 0 | 0.6 |
| No serious health problems were reported at tested doses of an experimental liver drug - Stock Titan | No serious health problems were reported at tested doses of an experimental liver drug Stock Titan | View source ↗ | Stock Titan | Aug 13, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance | Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| ASMB Forecast — Price Target — Prediction for 2027 - TradingView | ASMB Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance | We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely Yahoo Finance | View source ↗ | Yahoo Finance | May 11, 2026 | neutral | 0 | 0.6 |
| Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Stocktwits | Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs Stocktwits | View source ↗ | Stocktwits | Dec 22, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 8, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.